$620.70
0.97% today
Nasdaq, Apr 28, 03:47 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$614.76
+9.24 1.53% 1M
+57.93 10.40% 6M
-0.24 0.04% YTD
+246.16 66.78% 1Y
+295.04 92.28% 3Y
+468.62 320.67% 5Y
+591.76 2,572.87% 10Y
Nasdaq, Closing price Fri, Apr 25 2025
+14.25 2.37%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $37.54b
Enterprise Value $34.20b
P/E (TTM) P/E ratio 44.26
EV/FCF (TTM) EV/FCF 1,264.22
EV/Sales (TTM) EV/Sales 15.64
P/S ratio (TTM) P/S ratio 17.17
P/B ratio (TTM) P/B ratio 6.79
Revenue growth (TTM) Revenue growth 78.01%
Revenue (TTM) Revenue $2.19b
EBIT (operating result TTM) EBIT $-75.73m
Free Cash Flow (TTM) Free Cash Flow $27.05m
EPS (TTM) EPS $13.89
P/E forward 53.50
P/S forward 10.42
EV/Sales forward 9.50
Short interest 4.13%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a argenx SE ADR forecast:

30x Buy
88%
4x Hold
12%

Analyst Opinions

34 Analysts have issued a argenx SE ADR forecast:

Buy
88%
Hold
12%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
2,186 2,186
78% 78%
100%
- Direct Costs 236 236
4% 4%
11%
1,950 1,950
95% 95%
89%
- Selling and Administrative Expenses 1,033 1,033
71% 71%
47%
- Research and Development Expense 975 975
29% 29%
45%
-58 -58
84% 84%
-3%
- Depreciation and Amortization 18 18
84% 84%
1%
EBIT (Operating Income) EBIT -76 -76
84% 84%
-3%
Net Profit 831 831
381% 381%
38%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
about 9 hours ago
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherla...
Neutral
GlobeNewsWire
17 days ago
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schip...
Positive
Investors Business Daily
17 days ago
Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment. The post Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug appeared first on Investor's Business Daily.
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today